MN management has changed in 2020 onwards thanks to two trials published in 2020-2021 that showed that cyclophosphamide/steroids is superior and rituximab is not the main player yet.
The figures below summarize the main points of the GN 2021 KDIGO update
Thursday, October 21, 2021
KDIGO 2021: GN Management Guidelines: Membranous Nephropathy
Labels:
glomerular diseases,
KDIGO guidelines,
membranous GN
Subscribe to:
Post Comments (Atom)
All Posts
-
▼
2021
(36)
-
▼
October
(8)
- KDIGO 2021- GN Management Guidelines: Infection as...
- In the News: Performance trends of Nephrology fell...
- KDIGO 2021- GN Management Guidelines: FSGS
- KDIGO 2021: GN Management Guidelines: Membranous N...
- Detective Nephron: Next Venture Oct 2021
- KDIGO 2021: GN Management Guidelines: IgA nephropathy
- Consult Rounds: Hyponatremia and AKI- need CRRT- w...
- In the NEWS: Immunotherapy and the Kidney( new dat...
-
▼
October
(8)
No comments:
Post a Comment